



# Taiwan

Special Report 2025

Xinyi District, Taipei City, Taiwan. Photo by Lisanto Unsplash.

## Taiwan's Resilience: Innovation, Adaptation, and Global Partnerships

Despite geopolitical tensions and shifting global markets, Taiwan continues to prove its resilience by innovating, diversifying, and deepening ties with the United States and other key partners.

### ● Navigating Uncertainty with Confidence

Taiwan has long been at the center of global attention, both for its strategic location and for its outsized role in the world economy. Today, the island faces headwinds ranging from slowing global growth to intensifying US-China competition. Yet Taiwan's story is not one of fragility, it is one of adaptability.

While trade disruptions and inflation have reshaped supply chains, Taiwan has responded by doubling down on high-value sectors. Electronics, healthcare, and precision machinery remain pillars of growth, while green energy and biotech are emerging as new engines. This adaptability is not accidental; it is the product of decades of investment in education, technology, and strong partnerships.

### ● The United States: Taiwan's Strategic Anchor

The United States remains one of Taiwan's most important partners, accounting for around 15% of exports and forming the backbone of bilateral collaboration in strategic industries. The Chips and Science Act has further cemented semiconductor cooperation, but the relationship extends far beyond chips.

Taiwanese companies in precision engineering, biotech, and digital health are actively engaging with US partners. For example, AcroViz, a brain health innovator, is working with American hospitals to validate its AI-powered brain age diagnostics. "The U.S. is critical for us," said AcroViz CEO Isaac Tseng. "It's not only a vast market, but also the global benchmark for scientific validation."

Taiwan's path to the U.S. doesn't just run through semiconductors—it increasingly runs through regulated, evidence-driven healthcare. That is why Taiwanese founders treat the U.S. as a proving ground for clinical science and commercialization. AcroViz's

Isaac Tseng says the company is aligning its product roadmap to U.S. standards while scaling domestically to build population-level datasets. "We aim to expand MRI-capable sites from two to six across Taiwan so more people can access the Brain Age Examination conveniently," Tseng noted. "And we see AI not just as a diagnostic tool but as an ongoing companion for brain-health management—an approach that resonates with U.S. partners focused on prevention and outcomes."

### ● Innovation as a Survival Strategy

Resilience in Taiwan is deeply tied to its culture of innovation. From small labs to global enterprises, Taiwanese companies embrace the philosophy that constant reinvention is the only path forward.

Healthcare firms are developing cutting-edge diagnostic tools, manufacturers are integrating AI into traditional production, and universities are fostering cross-border research collaborations. This culture ensures that Taiwanese products and services remain competitive even in saturated or price-sensitive markets.

Everising Machine Company, a leader in industrial saws, has weathered fluctuations in global demand by pushing technological upgrades. "We are not competing on price; we are competing on innovation and service," explained Sam Chao, Chairman of Everising. "That's how Taiwanese companies win, even in difficult times."

### ● Supply Chains Built on Trust

Taiwan's unique advantage lies in its tightly knit supply chains. Unlike larger economies, Taiwan's industrial ecosystem is geographically compact, allowing companies to collaborate, adapt, and deliver at a speed unmatched elsewhere.

Semiconductors remain the flagship, but the network extends to packaging, testing, advanced plastics, and niche machinery. This ecosystem is the backbone of Taiwan's resilience, enabling it to pivot when markets shift or when disruptions occur.

CKPlas, which supplies advanced plastic injection solutions for semiconductor packaging, is a case in point. "We are a mid-sized company, but our design and responsiveness give global clients the confidence to trust us," said President Chih-Mao Chiang. "Taiwan's supply chain is strong because of companies like ours working hand in hand with industry leaders."

Speed and precision are the currency of trust in Taiwan's industrial ecosystem, especially in advanced packaging and materials where design tweaks ripple across entire

fabs. "We're a plastic injection specialist that designs and builds our molds in-house. That lets us respond to customer changes quickly and help them hit tight launch windows," says Chiang, adding that internationalization is a when, not if decision tied to customer pull: "The big clients move first. We'll follow them carefully, our principle is simple: do the job well, move when it truly helps customers, and keep improving every cycle."

### ● Digital Transformation in Manufacturing

Global competition is no longer about who can produce more, but who can produce smarter. Taiwanese manufacturers are embracing Industry 4.0 principles—integrating sensors, AI, and cloud systems to create intelligent, efficient production lines.

Techmation, a 40-year-old automation pioneer, illustrates this shift. The company has grown from producing injection molding controllers to developing entire automation ecosystems and renewable energy solutions. "Because we own 80 to 90% of our technology, from chips to systems, we are less vulnerable to external shocks," noted CTO Jerry Hsiung. "That independence allows us to innovate quickly and support both U.S. and Chinese clients."

Automation leaders are also de-risking their tech stacks to stay agile across markets. Hsiung says the company's strategy is to control critical IP and push intelligence to the edge. "That depth of in-house capability means we can localize fast without redesigning the core," he explained. "We're expanding from plastics into metal forming and general automation, pairing edge controllers with cloud analytics so factories can predict failures, reduce scrap, and redeploy scarce labor to higher-value work." The philosophy ties back to a simple mission: "Bring the best technology to traditional manufacturing and make it smarter, step by step."

### ● Demographic Challenges and Healthcare Opportunities

Like many advanced economies, Taiwan faces demographic challenges. With over 20% of the population now over 65, the healthcare system must adapt rapidly. Yet what might appear as a burden is increasingly viewed as an opportunity.

Hospitals, biotech startups, and research centers are using Taiwan's universal healthcare system and fully digital records to advance precision medicine, clinical trials, and telehealth solutions. These capabilities not only serve domestic needs but also make Taiwan an attractive partner for global pharmaceutical companies and healthcare providers.

The result is a new wave of internationally minded health innovators, such as AcroViz in brain health and Usoon Clinic in fertility care, which are reaching overseas patients while building on Taiwan's strong medical reputation.

Taiwan's aging curve is sharpening focus on measurable prevention, a domain where local innovators see global relevance. AcroViz's Tseng frames it as a national and international mandate: "Our research shows the younger the brain age, the healthier the brain and the lower the dementia risk. By 2035, our goal is to help reduce projected dementia cases in Taiwan by 50,000 through earlier detection and targeted interventions." The same data pipelines underpin partnerships abroad. "Validating brain-age biomarkers with U.S. institutions is essential," Tseng added. "It's how we convert AI insights into clinical decisions that improve lives at scale."

### ● A Balancing Act Between Giants

Geopolitical tensions between the U.S. and China place Taiwan in a delicate position. Yet rather than seeing itself as trapped, Taiwan positions itself as a bridge. The strategy is pragmatic: maintain competitiveness in China, expand presence in the U.S., and diversify into Southeast Asia, India, and Europe.

This balancing act is not easy, but Taiwanese business leaders remain pragmatic and optimistic. "We try to be friends with everyone," said Techmation's Hsiung. "Taiwan's strength is that we absorb global technologies and integrate them into manufacturing in ways that benefit both East and West."

### ● Looking Ahead: Resilience as a Growth Model

The coming years will test Taiwan. Rising labor costs, demographic shifts, and external political pressures are undeniable realities. Yet the island's track record shows that each challenge has become a catalyst for reinvention.

From precision manufacturing to biotech, Taiwanese companies are strengthening global partnerships, particularly with the United States. CKPlas supports the semiconductor backbone, Everising ensures industrial quality, Techmation drives digital transformation, and AcroViz pushes medical frontiers. Together, they reflect the island's broader story of resilience and innovation. It is not simply about survival, it is about turning constraints into strengths. As Sam Chao of Everising put it, "We see challenges as opportunities to raise the bar." ■

#### STAFF

**Pablo Martinez Matosas**  
CEO

**Javier Madero**

Editorial Director

**Maricruz Rojas Felix**

Creative Director and Designer

**Matias Godoy**

Chief Editor

**Giangina Orsini**

Writer



**AcroViz**  
Technology  
上頂醫學影像科技





# From Taipei to Washington: Taiwan’s Biomedical Push for Global Recognition

Taiwan’s biomedical innovators and hospitals are accelerating efforts to secure U.S. FDA approvals and forge partnerships with American institutions, aiming to expand access to international markets and strengthen Taiwan’s role in global healthcare.

● **Taiwan’s biomedical and healthcare sectors are entering a pivotal phase.** The island, already renowned for its excellence in technology and manufacturing, is applying the same spirit of innovation to life sciences and medicine. For local biotech firms, U.S. Food and Drug Administration (FDA) approval has become the gold standard, an entry ticket to the world’s most advanced and lucrative healthcare market. At the same time, Taiwan’s hospitals are increasingly looking outward, seeking alliances with U.S. medical centers, research institutes, and pharmaceutical companies to expand their influence, participate in clinical trials, and attract international patients.

● **FDA Approval as a Gateway to the World** For Taiwan’s biomedical companies, U.S. FDA approval is far more than a regulatory checkbox. It represents a strategic milestone, validating the safety, efficacy, and global readiness of their products. The FDA’s reputation for rigorous evaluation makes it the gold standard in international healthcare. Once granted, approval opens doors not only to the American market but also to other regions, where regulators often look to U.S. benchmarks when evaluating new drugs, devices, or therapies.

The pursuit of FDA clearance is not easy. It requires years of research, preclinical testing, large-scale animal studies, and expensive regulatory submissions. Yet for many Taiwanese companies, the investment is worth it. “The U.S. FDA is the gold standard,” explained Grace Li, CEO of Amelio Biomedical, a Taipei-based company developing breakthrough applications of its proprietary MAX (Metal Amino Click Synthesis) technology. “Getting approved by the FDA validates not just safety and efficacy, it signals global readiness.”

Amelio Biomedical is currently preparing a 510(k) submission for its next-generation hemostatic technology, Real Seal, designed to stop massive bleeding in seconds. The company has been in contact with the U.S. Department of Defense through programs linking medical innovators with battlefield applications. Li says this pathway exemplifies how FDA approval is about more than commercial sales: it is about credibility, partnerships, and alignment with America’s strategic healthcare priorities.

The same story echoes across Taiwan’s biotech scene. From medical aesthetics firms developing biomaterials to diagnostics companies working on cancer detection tools, FDA approval serves as both validation and leverage. A company that passes the FDA’s scrutiny can approach global investors, attract international distributors, and participate in multi-center trials with far greater ease.

But the journey is demanding. Taiwanese firms face cost constraints, complex documentation processes, and the challenge of aligning their research data with FDA expectations. This often requires collaboration with U.S.-based Contract Research Organizations (CROs) and clinical trial specialists. Some firms have already established offices or laboratories in the United States, building bridges that make the regulatory process smoother.

Despite the hurdles, the determination is palpable. The National Development Council and Taiwan’s Ministry of Health and Welfare have been promoting programs to help domestic companies enter global markets. Initiatives such as fast-tracked grants, matchmaking with U.S. institutions, and support for regulatory consulting are helping companies mitigate the costs and risks of FDA applications.

For many, FDA approval is not just about access to American patients. It also ensures Taiwan’s biomedical innovations can stand alongside those from global leaders like the U.S., Europe, and Japan. “We don’t see MAX as just an invention,” Li emphasized. “It’s a new class of molecular infrastructure with applications across healthcare and agriculture. But FDA approval is what will allow us to scale it globally.”

● **Hospitals Building Bridges Across the Pacific** While biomedical firms look to the U.S. FDA for global validation, Taiwan’s hospitals are seeking growth through partnerships and collaborations with American institutions. For

them, the U.S. represents not just a source of advanced medical technologies but also a partner in clinical research, training, and international patient services.

Taiwan’s healthcare system is consistently ranked among the world’s best, with universal coverage reaching 99.9% of the population. Yet Taiwanese hospitals know that excellence at home is only part of the equation. To compete with global medical hubs like Singapore or South Korea, they must expand their international footprint and build stronger connections with U.S. hospitals, universities, and pharmaceutical companies.

This drive is especially visible in the area of clinical trials. Taiwan’s fully digital medical records system, often written in English, provides a valuable advantage for data collection and sharing. American pharmaceutical companies looking to accelerate their Asia-Pacific studies increasingly view Taiwanese hospitals as attractive sites for collaboration. The availability of diverse patient cohorts, coupled with high standards of care, makes Taiwan a natural partner for clinical research.

Cathay General Hospital, one of Taiwan’s leading private hospitals, has been actively pursuing this path. “We see collaboration with U.S. hospitals and pharma companies as a way to bring more opportunities to our patients,” said Dr. Chih-Cheng Chien, Superintendent of Cathay General Hospital. “Through joint clinical trials, we can give Taiwanese patients access to cutting-edge therapies earlier, while also contributing to global medical research.”

The trend is not limited to large flagship hospitals in Taipei. Regional institutions across the island are also looking to position themselves as gateways for American partnerships. For example, hospitals in Kaohsiung and Taichung emphasize their geographic advantages, offering access to different patient demographics and regional industries. They view alliances with U.S. centers not just as clinical trial collaborations but as opportunities to build medical tourism pipelines, attract overseas patients, and exchange talent.

One of the most compelling arguments for U.S.-Taiwan hospital partnerships lies in the complementary strengths of each side. American institutions bring resources, research budgets, and established reputations in international medicine. Taiwanese hospitals contribute efficiency, cost-effectiveness, and technological integration that few countries can match. Together, they create a synergy that can accelerate medical innovation and broaden patient access worldwide.

Taiwanese hospitals are also expanding their involvement in specialized areas where global demand is surging. Oncology, regenerative medicine, and genomics are high on the agenda. By partnering with U.S. cancer centers and biotech companies, Taiwanese hospitals can expand their clinical trial portfolios while building expertise that benefits both local and international patients.

As Dr. Chien summarized, “Partnership is no longer optional, it’s essential. Healthcare challenges are global, and solutions must be built across borders. Taiwan has the expertise, the infrastructure, and the will to contribute. What we need are more opportunities to connect with American partners and work together.”

● **AI and Innovation at the Core of Taiwan’s Hospitals** If Taiwan’s biomedical companies see FDA approval as the key to global markets, its hospitals view innovation—particularly in artificial intelligence—as their pathway to international relevance. Across the island, healthcare providers are investing heavily in digital transformation, smart hospital technologies, and AI-assisted diagnostics, with the dual goal of improving patient care and making themselves more attractive partners for global research alliances.

Mackay Memorial Hospital, founded over 140 years ago by Canadian missionary George Leslie Mackay, epitomizes this blend of tradition and modernity. Ranked among Taiwan’s top ten hospitals and listed in Newsweek’s “World’s Best Hospitals 2024,” Mackay Memorial Hospital has embraced AI as a core driver of its future. Superintendent Dr. Wen-Han Chang explained the vision: “We are transforming Mackay

through four priorities, talent, technology, transformation, and transparency. AI is not just a tool for us, it’s a strategic pillar to raise our quality of care and extend our global reach.”

These digital capabilities position Mackay Memorial Hospital and other Taiwanese hospitals as valuable partners for U.S. institutions. With English-language medical records, robust data-sharing practices, and a highly digitized national healthcare system, Taiwan offers a research environment that can accelerate trials in oncology, cardiology, and rare diseases. This is particularly attractive for U.S. biopharmaceutical companies under pressure to generate evidence quickly and cost-effectively.

Importantly, AI in Taiwan’s hospitals is framed not as a replacement for physicians but as an augmentation of their abilities. “AI and technology are critical, but they must enhance human care, not replace it,” Dr. Chang emphasized. “Every AI system we deploy includes manual oversight, ensuring that technology serves the doctor-patient relationship, not the other way around.”

Other hospitals echo this philosophy. Institutions in Kaohsiung, Taichung, and Hsinchu are rolling out AI-supported health management platforms that integrate data from wearables, imaging scans, and genomic sequencing. By combining these sources, they can generate personalized risk assessments and preventive care plans, supporting Taiwan’s shift from treatment to proactive health management.

The embrace of AI also reflects Taiwan’s broader national strengths. As the global leader in semiconductors and advanced ICT, the island is uniquely positioned to merge cutting-edge hardware with healthcare applications. This creates opportunities for cross-sector partnerships between hospitals, tech companies, and device manufacturers—a synergy few other countries can match.

For U.S. partners, these advancements mean access to hospitals that are not only clinically advanced but technologically forward-thinking. The potential collaborations range from joint AI research projects to co-developing medical devices and software platforms that can be commercialized globally.

As Dr. Chang concluded, “We see AI as a bridge. It connects Taiwan’s medical tradition with its technological future, and it connects our hospitals with global partners who share the same vision of patient-centered innovation.”

● **Genomics and the Rise of Preventive Healthcare** Taiwan’s next great leap in healthcare may not lie in treating diseases after they occur, but in preventing them before they manifest. A growing number of hospitals are embracing genomic medicine and personalized prevention strategies, making use of the island’s advanced laboratories and falling costs of sequencing technology.

This shift reflects both necessity and opportunity. Taiwan faces a rapidly aging population—over 20% of its citizens are now over 65—and rising prevalence of lifestyle-related illnesses such as diabetes, obesity, and cardiovascular disease. Genomic screening offers a way to detect risks earlier and craft individualized health plans. It also represents a chance for Taiwan to position itself at the forefront of preventive healthcare in Asia, a field where the U.S. remains a natural partner for research and collaboration.

Kaohsiung Municipal Siaogang Hospital, located in southern Taiwan, is among the institutions pioneering this approach. Superintendent Dr. Chih-Hsing Hung, believes that the genomic revolution is essential to the future of medicine. “Traditionally, we screened patients for diseases with a series of standard tests. Today, we can analyze their genes and identify risks long before symptoms appear,” he said. “This allows us to design checkup plans tailored to each individual’s unique genetic profile.”

Beyond genetics, Kaohsiung Municipal Siaogang Hospital is also emphasizing lifestyle medicine. Teams of physicians, nutritionists, and health coaches work with patients to address risk factors such as diet, exercise,

and stress. Genomic results are combined with wearable device data and traditional screenings, creating a comprehensive picture of health. The long-term goal is to reduce disability and healthcare costs by catching conditions early.

AI is playing a role here as well. The hospital is collaborating with software developers to build platforms that integrate physiological data—heart rate, oxygen saturation, and even ECG patterns—into personal health apps. Patients can carry their own health information with them, monitor progress, and consult with physicians remotely. “No one should be more responsible for your health than yourself,” Dr. Hung emphasized. “Technology gives us the tools to empower patients to take control.”

This vision aligns with broader U.S. trends in precision medicine, where hospitals and research centers are also racing to apply genomic insights to preventive care. Partnerships between Taiwanese and American institutions could accelerate the validation of genomic biomarkers and create cross-border clinical databases with diverse populations.

● **Connecting Care Across Borders** Taiwan’s biomedical landscape is not only about technology and products; it is equally about forging the right partnerships. Increasingly, hospitals across the island are looking outward, aligning with U.S. institutions and pharmaceutical firms to ensure that their expertise has global resonance.

Kaohsiung Municipal Siaogang Hospital, managed by Kaohsiung Medical University, illustrates this outward-looking approach. As a 600-bed regional teaching hospital located in Kaohsiung’s key industrial district, the hospital is expanding to nearly 700 beds while strengthening its specialized programs in occupational health, environmental medicine, and elderly care. “Our goal is to improve the health of people in the industrial community, while also preparing for Taiwan’s super-aging society,” says Superintendent Dr. Chih-Hsing Hung.

One pioneering initiative is the hospital’s chewing and swallowing rehabilitation program, the first of its kind in Taiwan. Built through collaboration with Japanese institutions and now shared with partners in Southeast Asia, the program brings together a multidisciplinary team to tackle a common but often overlooked health risk for older adults. “We created a team approach to help elderly patients eat and swallow safely, reducing risks of choking and improving quality of life,” Dr. Hung explains. “This expertise is now being exported to Vietnam and other countries.”

Beyond clinical specialties, Kaohsiung Municipal Siaogang Hospital is embracing smart hospital innovation and international collaboration. The hospital has developed a “Lung Healthy Clinic” that integrates real-time air pollution data into patient records, allowing physicians to adjust treatments based on environmental exposures. It is also piloting AI-enabled diagnostic tools and portable devices for infectious disease detection. Such innovations position the hospital as a valuable partner for U.S. and global institutions interested in occupational health, aging care, and smart medicine.

Looking to the future, Dr. Hung emphasizes that partnerships will be essential as Kaohsiung Municipal Siaogang Hospital works toward upgrading from a regional hospital to a full medical center. “To reach the next level, we must expand our international cooperation, clinical trial capacity, and smart healthcare services,” he notes. “We welcome opportunities to collaborate with U.S. hospitals, universities, and companies to jointly advance medical innovation.”

The message to potential partners is clear: Taiwan’s medical institutions, including Kaohsiung Municipal Siaogang Hospital, are open for collaboration in areas such as clinical trials, AI-driven healthcare, sustainable hospital practices, and international medical education. For U.S. hospitals, pharmaceutical companies, and academic centers, the opportunity is not only to work with a leading regional institution, but also to join in shaping the future of global healthcare. ■





# Pushing the Frontiers of Cancer Care

The National Taiwan University Cancer Center in Taipei is redefining global standards for oncology treatment and research.



NTUCC's senior medical leadership, exemplifying a commitment to clinical excellence, academic distinction, and visionary healthcare leadership.

**Backed by major philanthropic support, including significant donations from Terry Gou and the Yonglin Foundation, the National Taiwan University Cancer Center (NTUCC) has swiftly established itself as one of Asia's most advanced hubs for cancer care.** The landmark welcoming corridor and hall of NTUCC is now home to more than 1,100 staff, including 120 full-time doctors and around 300 affiliated specialists. NTUCC receives more than 4,000 new cancer patients annually, 90% of whom remain with the center throughout their treatment journey.

From the beginning, NTUCC has set its sights on offering not just hope, but cutting-edge treatment. “We don't consider our job done until patients can continue living their lives as if they weren't patients at all,” said Dr. James Chih-Hsin Yang, Superintendent of NTUCC. “Our aim is to improve survival and reduce the physical and emotional burden of cancer.” NTUCC's vision is “to exhaust all possible resources to meet cancer patient's total health needs”.

A hallmark of NTUCC's approach is its investment in world-class equipment. It is the home of the country's most advanced diagnostic, radiation and isotope therapy facilities. The computerized tomography equipped bronchoscopy room is one of the first designs in the world for invasive lung nodule diagnosis and treatment. The center's proton therapy system, sourced from Varian, is among the most precise cancer treatment tools available in the world. Though not yet reimbursed under Taiwan's national insurance, its value for treating pediatric, prostate, head-and-neck, and liver cancers is already evident.

The clinical strength of NTUCC lies in its multidisciplinary model, combining oncologists, pulmonologists, gastroenterologists, radiologists, and surgical oncologists with what Dr. Yang describes as “the most efficient pathology lab in Taiwan.” NTUCC's surgeons perform minimally invasive, highly precise procedures, including single-port thoracoscopic lung surgery, with over 70% of lung cancer cases diagnosed at stage one, well above global averages. In fact, NTUCC treats more lung cancer patients annually than any other center in Taiwan. Our strength is combined care and “togetherness”. We see the same patients in the same clinic on the same date and make treatment decisions together with the patient and family in one afternoon.

Internationally, NTUCC has positioned itself as a key partner in early-stage drug development. The center leads over 50 clinical trials and its physicians serve as global advisors to top pharmaceutical companies. It also hosts three major annual conferences, including the Asia Taiwan Phase I Oncology Conference, International Symposium for Lung Cancer Research and Spacial Multi-omic Workshop/Conference which gathers the region's leading cancer researchers.

“Our doors are open,” Dr. Yang emphasized. “Whether for partnerships in clinical trials or to welcome patients from across Asia, Europe or North America, we want to be a global resource for precision oncology.”



# Championing Precision Medicine and Global Outreach

Through cutting-edge genomic medicine, AI integration, and a strong focus on patient privacy, Taipei Beitou Health Management Hospital is redefining preventive care and medical tourism in Taiwan.



Taipei Beitou Health Management Hospital is steadily emerging as a regional leader in preventive and precision medicine.

**Established in December 2013 as a government-backed pilot project, Taipei Beitou Health Management Hospital is steadily emerging as a regional leader in preventive and precision medicine.** With a team of around 100 medical professionals, the hospital was tasked from its inception with two core missions: delivering advanced preventive care and offering cosmetic medical services. Located in a quiet, green district near Yangmingshan National Park, the hospital was also designed to attract medical tourists, with a hotel integrated into the same building to offer seamless comfort and privacy.

From the beginning, the hospital's appeal extended beyond Taiwan. “About 10% of our patients come from overseas,” says Dr. Chao-Jung Wei, the hospital's medical director. “Initially, most international clients were from China, but due to recent political tensions, we now receive more patients from the U.S., Canada, Hong Kong, Macau, and Southeast Asia.”

Many international visitors are overseas Taiwanese—particularly those living on the U.S. West Coast—who return for checkups while visiting family. The hospital's discreet and efficient services have also made it a preferred destination for high-profile individuals. “Many of our clients are politicians or celebrities who value privacy and safety. We schedule appointments carefully so they don't encounter each other,” Wei explains.

In 2025, Taipei Beitou Health Management Hospital is doubling down on two strategic priorities: genomic medicine and lifestyle-based health promotion. “We are introducing genomic screening to identify patients with elevated

disease risk based on their DNA,” says Wei. “This allows us to tailor early screening plans, like starting cancer checks at 40 if necessary.”

The hospital is also targeting non-communicable lifestyle diseases such as obesity and heart disease. “We want to intervene early—before these become major health issues—by understanding patients' habits and guiding them toward better choices,” he adds.

Innovation remains central to the hospital's strategy. Advanced AI tools assist radiologists in detecting anomalies in medical imaging, and collaborations with software developers aim to integrate physiological data—such as oxygen levels, heart rate, and EKGs—into user-friendly health apps. “Technology helps patients monitor their own health. Ultimately, no one is more responsible for your health than you,” says Wei.


While the hospital is currently operating at 80–90% capacity, expansion is limited by space. Instead, it focuses on staying at the forefront of medical innovation. “We're replacing our MRI and CT scanners this year with some of the most advanced models globally,” Wei notes. “It's our way of staying ahead—by doing things right with the best tools available.”



臺北市北投健康管理醫院  
Taipei Beitou Health Management Hospital

# Fertility Care with Patient-Friendly Innovation

With fewer injections, high success rates, and a globally respected founder, Usoon Clinic is transforming fertility care in Taipei and beyond.



Usoon Clinic's top medical doctors.

**Founded in 2019, Usoon Clinic has treated over 5,000 patients in its first five years of operation.** Approximately 5% of its clientele comes from abroad, including from the United States, Canada, Hong Kong, Macau, Singapore, Malaysia, and Belgium, drawn by the clinic's reputation for effective care delivered with minimal physical and logistical burden.

A key factor behind the clinic's success is the experience and innovation of its leadership. Usoon Clinic's medical protocols are based on the decades-long clinical work of Dr. Hsin-Yang Li, who spent 28 years at Taipei Veterans General Hospital, including seven as Director of the Reproductive Center. There, Dr. Li specialized in complex in vitro fertilization (IVF) cases, which informed the development of a streamlined IVF protocol that has now become the clinic's signature.

This protocol, published in leading medical journals, reduces the number of hormone injections from the typical 10–20 to just 3–5, without compromising success rates. All injections are administered by nursing staff, removing the need for patients to self-inject and limiting clinic visits to as few as three per cycle. This model has proven particularly attractive for working professionals and international patients seeking efficient, expert care. By significantly easing the treatment process, Usoon has removed a major barrier for many couples and individuals who might otherwise delay or avoid fertility treatment altogether.

Usoon Clinic is also recognized for its work with azoospermia patients—men with no detectable sperm in their semen. Experienced embryologists search for viable sperm in surgically extracted testicular tissue under a microscope—sometimes for 10–20 hours in difficult cases. “This can be very challenging,” Dr. Li explains. “But we've helped many men, including overseas patients, become biological fathers using their own sperm.” He adds, “In some cases, patients were told in their home countries that there was no chance, but we were still able to find healthy sperm and proceed with ICSI.”

As part of its international strategy, the clinic offers online consultations and is open to future partnerships with overseas institutions. With a long track record of participation in events like the American Society for Reproductive Medicine (ASRM) annual meetings, Usoon Clinic is positioning itself as a collaborative, globally minded center of excellence.

“We want global patients and partners to know they'll be treated with compassion, professionalism, and minimal disruption to their lives,” says Dr. Li. “At Usoon, every treatment plan is designed to support the patient—medically and emotionally—every step of the way.”



# From Taiwan to the World: A MedTech Firm on the Rise

A-Top Health Biotech is scaling fast with a regulatory push, in-house production, and global ambitions.



A-Top Health Biotech CEO alongside the pioneering R&D team driving innovation.

**Founded in 2021, A-Top Health Biotech is emerging as a bold innovator in Taiwan's growing medical aesthetics and regenerative biotech sector.** Under the leadership of Olivia Tseng—Founder, Chairman, and CEO—the company is preparing to take a major leap forward with the FDA submission of its flagship product, Jouvence, while simultaneously expanding operations and workforce.

“We're still in the development stage, but at a very late point,” said Tseng. “Right now, I'm compiling the final documents to submit our 510(k) application to the FDA by the end of August or early September 2025.”

Jouvence, a skin-rejuvenating product for aesthetic and medical use, has been the company's primary focus, being the first thread to provide strong skin anchoring without skin piercing. Beyond biomaterials, A-Top is also developing AI to assist physicians by modeling surgical outcomes. The system can, for instance, predict facial volume and contour changes after Jouvence thread placement, helping surgeons optimize treatment plans.

A-Top's R&D has until now operated out of partner facilities, but the company has begun transitioning to full in-house capabilities. A new manufacturing site—just two blocks from their current location—is under construction, and the team is moving into a larger office to accommodate projected headcount growth.

“We currently have 13 employees and expect to at least double that by early next year,” said Tseng. “The new office is necessary, we're outgrow-

ing our current space.” The company also plans to build cleanroom facilities and install advanced instrumentation to scale production internally.

The company sees FDA approval as both a regulatory benchmark and a strategic launchpad. “For biotech companies in the Asia-Pacific, the U.S. FDA is the gold standard,” explained Tseng. “Getting approved by the FDA validates not just safety and efficacy, it signals global readiness.”

To enter the U.S. market effectively, A-Top is pursuing partnerships with local consultants, plastic surgeons, and dermatologists. “We're reaching out to surgeons in the U.S. to understand how our products align with their protocols,” Tseng added. “Their feedback is vital to refining the design.”

A-Top has also initiated collaboration with U.S.-based CRO NAMSA for large-animal studies and regulatory advisory services. The relationship is expected to evolve into broader support as the company advances through additional regulatory stages.

While Jouvence remains the company's priority, Tseng confirmed that a second product is under early-stage development, reinforcing A-Top's deep commitment to innovation. “R&D is at the heart of what we do,” she said. “We want to change what's possible in regenerative medicine.”





# The Quiet Revolution: How AI Is Powering Taiwan’s Next Wave of Biotech and Medical Innovation

Taiwan’s health-innovation engine is shifting up a gear. Across hospitals, clinics, and precision-manufacturing firms, artificial intelligence is moving from pilots to daily practice.

**The country’s most compelling advances aren’t about replacing people with code; they’re about building human-centered systems where AI makes skilled clinicians and engineers better.** Medical imaging is leading the shift. At Taipei Beitou Health Management Hospital, Superintendent Dr. Chao-Jung Wei explains: “I read a lot of images every day. AI now acts as a second reader—flagging subtle findings and double-checking my work. It’s not replacing clinical judgment; it’s reinforcing it.”

This co-pilot model aligns with Taiwan’s mature digital infrastructure. With electronic medical records and standardized imaging archives already in place, inference engines slot naturally into workflows. Clinicians gain triage support while administrators harvest cleaner data for quality improvement and research.

● **Human-Centered by Design**

The most counterintuitive theme in Taiwan’s AI journey is restraint. Usoon Clinic in Taipei has streamlined IVF protocols, trimming hormone injections from 10–20 down to just 3–5, all administered in-clinic. “Patients appreciate not only the reduced medication, but the simplicity of the whole process,” says founder Dr. Hsin-Yang Li.

At Vision Eye Center, Dr. Tsong-Chi Chang emphasizes predictable outcomes and patient confidence in refractive laser surgery. “The biggest jump patients feel is freedom—reading and driving without glasses. The tech matters, but the experience matters more,” he notes.

Digital Twins and Predictive Planning  
AI’s next frontier is pre-operative planning. A-Top Health Biotech is developing software that models volume and contour changes for thread-based facial procedures. “Our goal isn’t to automate decisions; it’s to

give surgeons a clearer map,” says founder and Chairperson Olivia Tseng. “It’s human in the loop from start to finish.”

AI in medicine starts long before patients enter a clinic. Taiwan’s machine-tool ecosystem is embedding AI and IoT, producing higher-precision components for medical devices. Hosea Precision in Taichung is one example. “We are using AI tools to reduce costs and accelerate product development,” says General Manager George Wei. “Moving from standard products to custom-made solutions lets us support different regional needs while preserving precision.”

● **Data With a Purpose**

General Biologicals Corporation (GBC) is anchoring Taiwan’s push into precision health. Its CellBio™ platform detects circulating tumor cells (CTCs) for early cancer monitoring. “Ninety percent of cancer-related deaths are caused by circulating tumor cells. Our goal is to give people a powerful tool for early detection and prevention,” says CEO TC Lin.

By generating real-world data through its CLIA-certified lab in San Diego and clinical operations in Taiwan, GBC is building the evidence base that will drive AI-powered oncology.

● **What Comes Next**

The rise of AI in Taiwan’s biotech and medical sectors looks less like disruption and more like steady, practical progress. From radiology reads that miss less, to IVF protocols that are simpler, to smarter machine tools that improve device safety, Taiwan is applying AI with purpose.

As Olivia Tseng sums it up: “It’s human in the loop from start to finish.” Or as George Wei adds from the shop floor: “Good products always have a place.” ■

# Taiwan Clinic Pioneers Breakthrough Laser Solution for Age-Related Vision Loss

For decades, turning 45 meant choosing between reading glasses or undergoing intraocular lens (IOL) replacement surgery to correct presbyopia. But now, a new option is emerging.



Dr. Tsong-Chi Chang, founder and CEO of Vision Eye Center 遠見眼科.

**In Taiwan, Vision Eye Center 遠見眼科 is rewriting the rules by introducing and refining the PRESBYOND LBV laser procedure—a groundbreaking method designed to help patients who suffer from both nearsightedness and age-related farsightedness (presbyopia).** This laser solution offers a lens-preserving alternative that keeps the natural eye structure intact while restoring clear vision for both near and far distances. At the forefront of this innovation is Dr. Tsong-Chi Chang, founder and CEO of Vision Eye Center, who performed Taiwan’s first successful LBV presbyopia laser correction. This landmark procedure earned him the title “Father of Laser Presbyopia LBV Surgery in Taiwan.” What makes this advancement so significant is that it challenges the long-held belief that laser surgery isn’t suitable for patients over 45—a misconception that previously led many to replace healthy lenses with artificial implants and sacrifice visual quality in exchange for the convenience of not wearing glasses.

Since then, Vision Eye Center has fine-tuned the procedure to better suit Asian eyes, which often present with combined myopia and presbyopia. The result: a rapid rise in demand across Taiwan, Hong Kong, and mainland China. Committed to advancing surgical safety and precision, Vision Eye Center has adopted a new generation of corneal

diagnostic technologies, such as dynamic corneal response analysis and epithelial thickness mapping, which help detect early signs of keratoconus and other abnormalities prior to surgery; as well as the latest femtosecond laser systems in cataract surgery and three new advanced measurement systems that enable more accurate presbyopic intraocular lens calculations. “Innovation in surgical techniques has always been the key driver of Vision Eye Center’s success. Our strategy is to make every procedure safer, more precise and efficient, using the best tools available,” says Dr. Chang.

This dedication has not gone unnoticed. In 2025, Vision Eye Center was named one of Asia’s Top Private Hospitals by Newsweek, and it was recently awarded third place for surgical innovation by the American Society of Cataract and Refractive Surgery (ASCRS). The clinic also serves as a certified training and development hub for LBV technology in the Asia-Pacific region. “We’re not just building clinics,” says Dr. Chang. “We’re creating a world-class ophthalmology platform for Asia—one that blends clinical excellence, sustainable innovation, and global knowledge sharing.” ■



# Advancing Cancer Prevention

General Biologicals Corporation (GBC) is redefining cancer care with advanced CTC detection technology and a strategic push into international markets.

**Taiwan-based General Biologicals Corporation (GBC) is marking a new chapter in its growth story, driven by breakthroughs in cancer detection and strategic global expansion.** Known for its diagnostic solutions since its founding in 1984, GBC has recently focused its efforts on precision health, launching cutting-edge tools aimed at proactive disease prevention.

At the forefront of GBC’s recent achievements is its pioneering CTC (circulating tumor cell) detection product, branded as CellBio™. The product has been recently acknowledged for its excellence and received the 2025 EDISON award in the USA. Designed for early cancer detection and ongoing monitoring, this technology addresses a critical challenge in oncology—identifying cancer cells in the bloodstream before they spread. Unlike traditional diagnostics that often detect cancer at later stages, CellBio™ enables continuous health monitoring to catch potential threats early. “Ninety percent of cancer-related deaths are caused by circulating tumor cells. Our goal is to give people a powerful tool for early detection and prevention,” said TC Lin, Chairman and CEO of GBC.

Already available in Taiwan for over three years, the CellBio™ platform has tested nearly 30,000 individuals. With Taiwan’s TFDA approval secured, GBC is now gathering real-world data to pursue US FDA clearance. The company’s CLIA-certified Danner Lab in San Diego plays a key role in this strategy, offering laboratory-developed testing services to build the necessary clinical evidence. “We believe using real-world data will make the FDA approval process more efficient,” Lin explained.

The expansion doesn’t stop there. GBC is preparing to inaugurate a new facility at AI Park in Hsinchu in 2025, reinforcing its presence in Taiwan’s biotechnology sector. The new site will house GMP manufacturing



GBC’s state-of-the-art facility located at AI Park in Hsinchu, Taiwan.

operations, while the company plans to rebuild and expand its current premises. “This move will increase our capacity and position us alongside leading technology companies in Taiwan,” Lin added.

Looking ahead, GBC is aligning its international strategy with market trends by planning localized manufacturing in North America. “For the U.S. market, domestic production is becoming essential to stay competitive,” Lin noted. The company is actively seeking partnerships in the U.S. and Canada to support this growth, particularly in logistics and healthcare.

Positioning itself beyond traditional diagnostics, GBC champions a shift from reactive care to precision health—an approach centered on proactive prevention rather than treatment. “We believe the future of healthcare is about staying ahead—using advanced technology to prevent illness before it starts, and giving people the tools to live healthier, longer lives,” Lin concluded. ■

# Precision, Innovation, and the Race to Stay Ahead in Global Manufacturing

Amid shifting global markets and rising competition, Hosea Precision is leveraging innovation, strategic partnerships, and Taiwan’s reputation for quality manufacturing to drive its next phase of international growth.

**Hosea Precision, a leading Taiwanese manufacturer of rotary and tilting tables for machine centers, is strengthening its global position through innovation, strategic partnerships, and a commitment to the “Made in Taiwan” brand.** Based in Taichung, with a team of around 50 employees, the company has steadily expanded its reach across Europe and Asia.

Traditionally focused on Europe, Hosea has adapted to shifting market conditions by diversifying its client base. The European market, once accounting for 60% of sales, has slowed, prompting a sharp increase in business with China. “Last year, China grew to represent 50% of our orders,” said General Manager George Wei. “We adjusted quickly to cover the decline in Europe.”

This shift followed several years of strategic recalibration. Hosea had previously worked with a U.S. distributor, but after a drawn-out negotiation ended with a surprise demand for price cuts, the company chose to pause its U.S. operations. “It was a tough lesson,” said Wei. “But it showed us the importance of long-term trust and mutual respect in partnerships.”

In the meantime, Hosea is keeping a close eye on U.S. market opportunities and actively seeking new partners. The company has also participated in international trade shows such as IMTS in Chicago, though past experiences have highlighted the challenges of gaining visibility without prime booth space. “Without the right exposure, it’s hard to showcase what we do,” Wei noted.

● **Smarter Machines, Stronger Alliances**

Hosea’s strategy emphasizes technological advancement to stay competitive amid global price pressures. Significant investment in AI and IoT is driving the development of intelligent machinery and customized solutions tailored to regional needs. “We are using AI tools to reduce costs and accelerate product development,” noted Wei. “Moving from standard products to custom-made solutions allows us to better serve markets like the US, Europe, and China.”

The company is also expanding its offering beyond rotary tables, using its expertise to support

manufacturers in integrating AIOT (Artificial Intelligence of Things) components into full machine systems. This positions Hosea not just as a parts supplier, but as a solutions provider at the forefront of smart manufacturing. “We’re helping our partners transition toward intelligent machines,” said Wei. “That’s where the market is going.”

Collaboration with local machine center manufacturers is another cornerstone of Hosea’s growth plan. By supporting Taiwanese partners in upgrading their production capabilities, Hosea is fostering a shift from price-based competition to precision and high functionality. “We see a great opportunity to help develop smarter machines,” Wei explained. “The market can no longer rely on low prices alone.”

● **Branding Beyond OEM**

A strong advocate for Taiwanese industry, Hosea is actively engaged in promoting its brand internationally. As a member of the Taiwan Branding Association, the company is working to move beyond OEM models and establish itself as a recognized name in precision engineering. “We want to show the world what Taiwanese companies can do,” said Wei. “Building our own brand is essential.”

While geopolitical tensions and economic uncertainties present challenges, Hosea remains focused on quality and innovation as key differentiators. The company is also exploring renewed entry into the US market through carefully selected partnerships. “Good products always have a place,” Wei affirmed. “With the right alliances and continuous innovation, Hosea is well-positioned to grow as a symbol of Taiwanese excellence.”

With a new generation of leaders embracing branding, technology, and international collaboration, Hosea is ready to step out from the shadows of OEM manufacturing. As Wei put it: “We’re not just building machines—we’re building identity, value, and trust.” ■

